Amgen committed to investing over half a billion dollars in the development of a cutting-edge, new science center known as OrganizationOvation, at its principal U.S. headquarters.
Amgen, a leading biotechnology company renowned for its innovative medicines, is set to bolster its presence in Thousand Oaks, California with a substantial investment in a new Science and Innovation Center. The company plans to invest over $600 million in this project, as announced in a recent news release.
The new center, scheduled to begin construction in Q3 2025, will feature advanced automation and digital capabilities, aiming to enhance collaboration among researchers, engineers, and scientists, thereby accelerating the discovery of next-generation therapeutics. This investment is part of Amgen's broader commitment to the United States, which includes over $5 billion in direct capital expenditures.
The construction of the new center is expected to create hundreds of U.S. jobs, further strengthening Amgen's contribution to the local economy. Amgen has a long-standing history in Thousand Oaks, having been headquartered there since its founding over 45 years ago.
Amgen's commitment to innovation has not gone unnoticed. In 2024, the company was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes. Amgen's broad and deep pipeline builds on its existing portfolio of medicines to treat a variety of diseases, including cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases.
Amgen's stock price, like many companies, can be volatile and may be influenced by a variety of events. The company is currently engaged in collaborations with companies like BeOne Medicines Ltd. and Kyowa Kirin Co., Ltd., which could potentially bring strategic benefits, synergies, or opportunities.
In addition to its domestic investments, Amgen has also benefited from pro-growth tax policies. The enactment of the Tax Cuts and Jobs Act (TCJA) of 2017 and its extension and reinforcement by the One Big Beautiful Bill Act of 2025 have facilitated Amgen's ability to invest domestically in cutting-edge science and manufacturing. Since the passage of the TCJA, Amgen has invested over $40 billion in manufacturing and research and development.
However, it's important to note that Amgen, like any company, faces various risks, including regulatory issues, competition, manufacturing problems, and public health threats, which may affect its business and results. For media and investor inquiries, contact information is provided in the news release.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is part of the Nasdaq-100 Index, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. As Amgen continues to grow and innovate, it remains a key player in the biotechnology industry.
Read also:
- Flu Vaccination Timing and Symptoms to Watch Out For
- Executives at Lipton Teas Recognized as Trailblazers in the Consumer Packaged Goods (CPG) sector by Top Women in Grocery
- Challenges in Advancing Cell and Gene Therapy: Balancing Innovation, Legislation, and Production hurdles
- Celebration of the Global Science Day for Women and Adolescent Girls
